Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate Compared to Placebo

Study Title
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Teva Identifier
MS-GA-301 | 2009-018084-27
ClinicalTrials.gov Identifier
NCT01067521
Study Status
Completed
Trial Condition(s)
Relapsing Remitting Multiple Sclerosis
Interventions
Drug: Glatiramer acetate (GA) | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 55 Years
Trial Duration
June 22, 2010 - May 12, 2017
Phase
Phase 3

Study Type

Interventional